Encouraging initial results for newer drugs to treat diffuse large B-cell lymphoma

MOR2018 and lenalidomide could be a new treatment combination for diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment.

Text that says Results

L-MIND is a phase 2 trial testing the combination of 2 newer drugs, MOR2018 and lenalidomide.

Previous clinical trials have shown that each of the drugs on their own is effective for DLBCL. This trial is testing whether the combination of both drugs can improve outcomes further for people with DLBCL who have limited treatment options.

Initial results for the first 31 people of 80 intended to be recruited were presented at the International Conference for Malignant Lymphoma (ICML) this month.

Promising results were reported, with around 6 in 10 people responding to treatment. However, more people are to be recruited and it is not yet known how long the response will last.

The treatment has been well tolerated so far, with the most common side effects reported as low blood counts (neutropenia, anaemia, thrombocytopenia), infections, diarrhoea, fever and rashes.

Find out more about the trial in our trial summary or search our database to find a trial that might be suitable for you.